Eric Sagonowsky

Editor

Eric Sagonowsky is an editor with FiercePharma and FierceVaccines. He joined the Fierce staff in November 2014 and covers topics such as drug pricing, biosimilars and product liability litigation.

Stories by Eric Sagonowsky

Merck teams with Brazilian vaccine institute for dengue work

by Eric Sagonowsky

Thursday, December 13, 2018

Merck & Co. struck a deal with Brazil's Butantan Institute to push ahead with their respective dengue development programs.

Mylan, Biocon inch closer to Lantus copycat launch

by Eric Sagonowsky

Thursday, December 13, 2018

After Merck abandoned its Lantus biosimilar, Mylan is still pressing forward and won a patent challenge against Sanofi.

FDA takes on insulin pricing with move to bolster competition

by Eric Sagonowsky

Wednesday, December 12, 2018

Insulin prices have grown significantly in recent years, and the FDA is moving to reclassify the products as biologics to boost competition.

Senator: Pfizer playing 'political games' with drug prices

by Eric Sagonowsky

Wednesday, December 12, 2018

Sen. Tammy Baldwin blasted Pfizer's plan to increase prices in January and called on the company to release details about its costs, plus more.

Remicade, biosim prices slip as competition heats up: analyst

by Eric Sagonowsky

Tuesday, December 11, 2018

As J&J vies with biosims to big-selling Remicade, prices across the category are falling, an analyst says—and Pfizer's Inflectra has tumbled the most.

J&J CEO: Amazon could shake up rebates and more for pharma

by Eric Sagonowsky

Tuesday, December 11, 2018

J&J CEO Alex Gorsky said Amazon could offer expertise in distribution as well as shake up reimbursement in a potential pharma entry.

Shingrix shortage to persist 'throughout 2019'

by Eric Sagonowsky

Tuesday, December 11, 2018

GlaxoSmithKline is working to boost its supply of shingles vaccine Shingrix, but in the meantime, a shortage will last until next year.

Generics 'cartel' probe expands to 300 drugs: report

by Eric Sagonowsky

Monday, December 10, 2018

Connecticut Assistant Attorney General Joseph Nielsen told The Washington Post the generic drug market is possibly the biggest "cartel" in U.S. history.

Akorn CEO exits after failing to salvage Fresenius deal

by Eric Sagonowsky

Monday, December 10, 2018

Akorn once again tried and failed to salvage its $4.3 billion merger with Fresenius, and now its CEO is bowing out.

U.S. drug spending grew less than 1% last year: CMS

by Eric Sagonowsky

Friday, December 7, 2018

The government is riled up about drug prices and promising to drive them down, but a CMS report shows retail drug spending grew just 0.4% last year.